Immunoglobulin M
Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures
Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology
IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data
IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644
IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes
IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus
Sanofi Downsizes IGM Antibody Deal, Reduces Oncology Focus
Sanofi, IGM Biosciences, antibody deal, oncology, downsizing, partnership